New US Federal Trade Commission chairman - Edith Ramirez - to be designated by President

3 March 2013

President Barack Obama intends to designate Edith Ramirez as Chairman of the Federal Trade Commission effective Monday, March 4, 2013. She takes over for outgoing Chairman Jon Leibowitz, who has served in the position since March 2, 2009, and has been a vociferous critic of patent settlements, or pay-for-delay deals, between originator pharma companies and generic drugmakers.

“I look forward to working with my fellow commissioners and the able FTC staff to continue the agency’s proud history of promoting vigorous competition and protecting consumers,” said Ms Ramirez, adding: “I also want to thank Chairman Leibowitz for his strong leadership. I welcome the opportunity to build on his legacy of active enforcement of our antitrust and consumer protection laws.”

Ms Ramirez became a commissioner of the FTC on April 5, 2010. At the FTC, she has focused on promoting competition and innovation in the technology and health care sectors, protecting vulnerable consumers from deceptive and unfair practices, and safeguarding consumer privacy.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK







Today's issue

Company Spotlight



More Features in Biotechnology